// App-Quantinova.ai

BSH2020‐EP‐008 : Estimating the relative treatment effect and corresponding cost‐effectiveness estimates of inotuzumab ozogamicin versus blinatumomab for adults with Philadelphia chromosome‐negative relapsed/refractory B‐cell acute lymphoblastic leukaemia in the United Kingdom

Researchers

Presenter

  • T. A. Russell-Smith

Principal Investigators

  • M. Cooper

  • I. van Oostrum

  • V. Welch

  • S. Critchlow

Medical Centers

  • Pfizer Inc, New York, NY

  • BresMed Health Solutions, Sheffield, United Kingdom

  • Ingress Health, Rotterdam, Netherlands

Locations

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Inotuzumab ozogamicin

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved